Recent Updates
Recently added Catalysts

Obinutuzumab and Pixantrone

Phase 2

Lymphoma, Non-Hodgkin | Small molecule | Oncology |Tango Therapeutics, Inc.|Last Updated: Mar 31, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment70

FDA Designations

No designations recorded

Clinical trial landscape

Obinutuzumab and Pixantrone · 1 trial · 1 indication

Phase 2 1
NCT02499003GOAL: GA101 Plus Pixantrone for Relapsed Aggressive LymphomaLymphoma, Non-Hodgkin
COMPLETED70 Analytics
PHASE2COMPLETED
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Lymphoma, Non-Hodgkin
NCT0249900370
Unlock trial analytics

Study Endpoints

Primary Endpoints

Objective overall response rate (ORR) after six treatment cycles or the individual end of treatment
30 weeks

The response to treatment is measured by results of computer tomography (CT) for measurable lesions and evaluation for non-measurable lesions after cycle 6 or at the individual end of treatment.

Secondary Endpoints

Safety of the combination treatment as measured by the rate of adverse events, which reflects tolerability of the treatment.
30 weeks
Percentage of patients completing the entire trial treatment
30 weeks
Evaluation of best response to trial treatment as measured as best response either during or post the entire treatment
30 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Obinutuzumab and PixantroneEXPERIMENTALObinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle

Interventions

NameTypeDescription
Obinutuzumab and PixantroneDRUGObinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Patients aged ≥ 18 years * Histologically proven diagnosis of diffuse large cell B-cell lymphoma (DLBCL), follicular lymphoma (FL) IIIB or transformed indolent lymphoma according to the World Health Organization classification (central pathology review) * Relapsed disease * Ea...

Countries:Germany
Unlock Eligibility Criteria

Frequently asked questions about Obinutuzumab and Pixantrone

What is Obinutuzumab and Pixantrone used for?

Obinutuzumab and Pixantrone is an investigational combination being studied for the treatment of Non-Hodgkin lymphoma. It is currently in Phase 2 clinical development. The combination is being evaluated in patients with relapsed aggressive lymphoma, as part of a clinical trial conducted in Germany.

Who makes Obinutuzumab and Pixantrone?

Obinutuzumab and Pixantrone is being developed by Tango Therapeutics, Inc. (NASDAQ: TNGX). The company is conducting clinical research on this combination for the treatment of Non-Hodgkin lymphoma.

What phase is Obinutuzumab and Pixantrone in?

Obinutuzumab and Pixantrone is in Phase 2 clinical development. It is an investigational combination therapy, not yet approved by regulatory authorities. A Phase 2 clinical trial has been completed to evaluate its safety and efficacy in patients with relapsed aggressive lymphoma.

What clinical trials is Obinutuzumab and Pixantrone in?

Obinutuzumab and Pixantrone has been studied in one clinical trial, NCT02499003, titled 'GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma'. This Phase 2 trial enrolled 70 participants with Non-Hodgkin lymphoma and has been completed. The trial was conducted in Germany.

Is Obinutuzumab and Pixantrone the same as GA101 plus pixantrone?

Yes, Obinutuzumab and Pixantrone is the same as GA101 plus pixantrone. The clinical trial NCT02499003 is titled 'GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma', indicating that GA101 refers to obinutuzumab in this combination.